Patents Examined by Quang Nguyen
  • Patent number: 8742085
    Abstract: A method for preparing a transgenic animal of simultaneous multiple-gene expression is provided. Additionally, a method for preparing a transgenic embryo, which introduces both phytase gene and human myxovirus resistant gene A into a target embryo, to obtain a transgenic embryo is provided. The transgenic animal of simultaneous multiple-gene expression can be achieved by transplanting the transgenic embryo into the body of a female target animal. A significant advantage of the foregoing methods, among many others, exists in that the simultaneous expression of multiple genes can be achieved in one transgenosis, which provides a convenient method for the preparation of combined-gene transferred animals.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: June 3, 2014
    Assignee: Institute of Animal Science, Chinese Academy of Agricultural Sciences
    Inventors: Kui Li, Huiming Ju, Junhua Fan, Lijing Bai, Yulian Mu, Shulin Yang, Zhonglin Tang, Wentao Cui
  • Patent number: 8716447
    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 6, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
  • Patent number: 8663971
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: March 4, 2014
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Patent number: 8632797
    Abstract: Embodiments of surgical grafts, and methods, for the delivery of therapeutic agents to a target tissue via acellular matrices, are described. In some embodiments, nonviable matrices are successful in preventing or lessening adhesion formation by guiding tissue repair and remodeling, while also providing the target tissue with therapeutic agents that can act as repair and remodeling factors. An exemplary method to modulate flexor tendon healing and provide elimination or reduction of fibrotic adhesions involves loading a freeze-dried flexor digitorum longus allograft with recombinant adeno-associated viral (rAAV) vectors for the targeted and transient expression of growth/differentiation factor 5 (GDF5).
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: January 21, 2014
    Assignee: University of Rochester
    Inventors: Hani A. Awad, Edward M. Schwarz
  • Patent number: 8628957
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 14, 2014
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Patent number: 8617534
    Abstract: The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 31, 2013
    Assignee: San Diego State University (SDSU) Foundation
    Inventors: Mark A. Sussman, John A. Muraski
  • Patent number: 8597945
    Abstract: A method of differentiating embryonic stem cells into ventral spinal progenitor cells is disclosed. In one embodiment, the invention comprises culturing a population of cells comprising a majority of cells that are characterized by an early rosette morphology and are Sox1?/Pax6+ in the presence of retinoic acid, wherein the cells express Hoxb4, but not Otx2 or Bf1.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: December 3, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Xue-Jun Li
  • Patent number: 8598331
    Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: December 3, 2013
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra
  • Patent number: 8562968
    Abstract: The present invention relates to the use of a composition containing stem cells as well as CD6 depleted stem cells for the induction of a tolerance to allogenic transplants and/or for the treatment of blood, immune, and cancer diseases for time-staggered application wherein first the stem cells are applied followed by application of the CD6 depleted stem cells. Furthermore, the present invention relates to a compound preparation containing stem cells and CD6 depleted stem cells.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: October 22, 2013
    Assignee: GSF-Forshungszentrum für Umwelt und Gesundheit, GmbH
    Inventors: Wolfgang Günther, Hans Jochen Kolb
  • Patent number: 8557515
    Abstract: The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: October 15, 2013
    Assignee: Thomas Jefferson University
    Inventors: Carlo Croce, George Calin
  • Patent number: 8529885
    Abstract: The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in in vivo gene therapy.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: September 10, 2013
    Assignees: Academisch Medisch Centrum, Institut National de la Sante et de la Recherche Medicale
    Inventors: Paul Peter Tak, Christian Jorgensen
  • Patent number: 8486695
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 16, 2013
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Patent number: 8436160
    Abstract: An isolated DNA sequence corresponding to a region of the SPARC gene human promoter from base pair ?513 to base pair +35 capable of driving the expression of a heterologous gene of interest, that can be associated to any other promoter sequence, such as radiation responsive sequence, hypoxia responsive sequence and free-radical responsive sequence. The invention also provides constructs and DNA recombinant expression viral vectors, comprising the isolated sequence of the SPARC gene human promoter and at least one heterologous gene operably linked thereto, wherein the promoter sequence drives the expression of the at least one heterologous gene in tumor cells. Pharmaceutical compositions and a method for treating tumors are also provided.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: May 7, 2013
    Assignees: Consejo Nacional de Investigaciones Cientificas y Tecnicas (Conicet), Fundacion Instituto Leloir
    Inventors: Osvaldo Luis Podhajcer, Eduardo Gustavo Alfredo Cafferata, Maria Veronica Lopez, Diego Luis Viale
  • Patent number: 8426168
    Abstract: The present invention relates to the preparation of a recombinant polypeptide, which polypeptide upon expression has been secreted into the periplasm of a transformed host cell. In particular, this invention relates to a process to enhance the extraction yield of the recombinant polypeptide from the periplasm before further downstream processing.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: April 23, 2013
    Assignee: Sandoz AG
    Inventors: Günter Stempfer, Norbert Palma
  • Patent number: 8420079
    Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: April 16, 2013
    Assignee: Grifols Therapeutics, Inc.
    Inventors: Jennifer Hunt, Valery Novokhatny
  • Patent number: 8383803
    Abstract: Isolated polynucleotides comprising a PITX3 promoter are provided, where a PITX3 regulatory element is operably joined to a PITX3 basal promoter utilizing a non-native spacing between the promoter and regulatory elements. The promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 26, 2013
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra
  • Patent number: 8383095
    Abstract: The present disclosure relates to the field of hematopoietic stem cell transplantation. More specifically, methods, compositions and kits for improving engraftment of stem cell transplants by administering myeloid progenitor cells are provided.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: February 26, 2013
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Julie Lynne Christensen, Holger Karsunky
  • Patent number: 8357832
    Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: January 22, 2013
    Assignee: National Health Research Institutes
    Inventors: Kurt M. Lin, Ing-Ming Chiu
  • Patent number: 8354268
    Abstract: The present invention provides genetically engineered strains of Pichiacapable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: January 15, 2013
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Patent number: 8318495
    Abstract: Genetically engineered hematopoietic progenitor cells that carry within them genes of interest, particularly for the expression of physiologically or pharmacologically active proteins. The hematopoietic progenitor cells are transduced in the presence of human mesenchymal stem cells which enhance transduction efficiency.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: November 27, 2012
    Assignee: Case Western Reserve University
    Inventor: Stanton L. Gerson